Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2021 | Prime time for Alzheimer’s disease research

Colin L. Masters • 11 Mar 2021
AD/PD 2021
Alzheimer’s Disease

Colin L. Masters, MD, Florey Institute of Neuroscience and Mental Health, Parkville, Australia, shares his message to young clinicians and researchers. Prof. Masters believes this is the best time to get involved with Alzheimer’s disease research. The diagnostic armamentarium is evolving, and the therapeutics strategies are progressing. This interview took place during the AD/PD™ 2021 conference.

More from Colin L. Masters

Better diagnostic methods and therapies for Alzheimer's disease
2:25
Better diagnostic methods and therapies for Alzheimer's disease
Colin L. Masters • 11 Mar 2021
Alzheimer's disease and β-Amyloid: new revelations
3:03
Alzheimer's disease and β-Amyloid: new revelations
Colin L. Masters • 11 Mar 2021
Evidence supporting the Aβ pathway in Alzheimer's disease
1:10
Evidence supporting the Aβ pathway in Alzheimer's disease
Colin L. Masters • 11 Mar 2021
Blood and CSF biomarkers for Alzheimer’s disease
1:42
Blood and CSF biomarkers for Alzheimer’s disease
Colin L. Masters • 11 Mar 2021

Related Videos

PCSK9-targeted therapies and the risk of stroke and dementia: a meta-analysis of RCTs
3:34
PCSK9-targeted therapies and the risk of stroke and dementia: a meta-analysis of RCTs
Vikash Jaiswal • 26 Aug 2026
How AI and data science are advancing obstructive sleep apnea management
2:23
How AI and data science are advancing obstructive sleep apnea management
Omonigho Michael Bubu • 15 Jun 2026
Obstructive sleep apnea and Alzheimer's disease risk: toward personalized care
5:40
Obstructive sleep apnea and Alzheimer's disease risk: toward personalized care
Omonigho Michael Bubu • 15 Jun 2026
The future of personalized Parkinson's disease care considering differing subtypes
3:10
The future of personalized Parkinson's disease care considering differing subtypes
Massimiliano Passaretti • 28 Jun 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals